1 citations · 1 across the 6 of their papers we have counts for
7 papers
A Cosine-Projection Framework for Choosing Among Cox HR, D-RMST, and Average-Hazard Tests in Survival Trials
Xiang Meng, Lu Tian, Hajime Uno
The log-rank/Cox hazard-ratio test remains the standard approach for the primary analysis of randomized trials with time-to-event endpoints and is fully efficient under proportiona…
Average Cause-Specific Hazard: A Censoring-Invariant Measure of Event Burden Under Competing Risks
Khondoker Nazmoon Nabi, Xiang Meng, Lu Tian +3
Competing events are common in clinical and epidemiologic studies, including semi-competing risks in which a terminal event such as death may follow a nonfatal event but also compe…
Comment on "Average Hazard as Harmonic Mean" by Chiba
Hajime Uno, Lu Tian, Miki Horiguchi +1
In a recent article published in Pharmaceutical Statistics, Chiba proposed a reinterpretation of the average hazard as a harmonic mean of the hazard function and questioned the val…
While-alive regression analysis of composite survival endpoints
Xi Fang, Hajime Uno, Fan Li
Composite endpoints, which combine two or more distinct outcomes, are frequently used in clinical trials to enhance the event rate and improve the statistical power. In the recent…
Comparative Effectiveness Research with Average Hazard for Censored Time-to-Event Outcomes: A Numerical Study
Hong Xiong, Jean Connors, Deb Schrag +1
The average hazard (AH), recently introduced by Uno and Horiguchi, represents a novel summary metric of event time distributions, conceptualized as the general censoring-free avera…
A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-to-Event Outcomes Using Average Hazard with Survival Weight
Zihan Qian, Lu Tian, Miki Horiguchi +1
Given the limitations of using the Cox hazard ratio to summarize the magnitude of the treatment effect, alternative measures that do not have these limitations are gaining attentio…
Assessing Delayed Treatment Benefits of Immunotherapy Using Long-Term Average Hazard: A Novel Test/Estimation Approach
Miki Horiguchi, Lu Tian, Kenneth L. Kehl +1
Delayed treatment effects on time-to-event outcomes have often been observed in randomized controlled studies of cancer immunotherapies. In the case of delayed onset of treatment e…